INNOVATIVE
LAB FOR
RESPONSIVE
CARE

A GLYCO-HUMANIZED ANTIBODY PLATFORM WITH EMBEDDED TECHNOLOGY THAT RENOVATES IMMUNOLOGICAL TREATMENTS

Innovative immunotherapy
XENOTHERA is addressing unmet medical needs with proprietary Glyco-Humanized Antibodies:

Genetic engineering of the bioproduction,
immunogen optimization
Enhanced therapeutic efficacy of GH-pAb validated pharmaceutical development,  stability for more than 3 years
Translational development program experience with 3 products in clinic.

Therapeutic domains:

Oncology
Immunology
Infectius (virus, bacteria)
Others

Executive team

A clinical stage Biotech

An agile company with a fast-paced development

XENOTHERA is a clinical stage biotech at the top of innovation, which creates new therapeutic modes in several indications. Our patented technological platform is built on our expertise in immunology and therapeutics. We develop innovative  approaches in immunotherapy with our platform  of Glyco-Humanized Polyclonal Antibodies (GH-pAb). Our antibodies are addressing major therapeutic needs in various domains, including oncology, immunosuppression, viral and bacterial infections. XENOTHERA’s platform allows short-time development thanks to our validated saled-up GMP platform, our in-house bioproduction facility, our clinical experience (400 patients have received GH-pAb today), our mastery of antigens and our regulatory experience. Within less than 8 years, XENOTHERA has brought to clinic LIS1, a novel induction treatment in Solid Organ Transplantation, addressing a $1Bn market, XAB05, a preventive anti- multidrug resistant bacteria GH-pAb, XAV19 an anti-COVID antibody dedicated to patients with moderate disease. XENOTHERA has accumulated preclinical evidence for the therapeutic effect of its oncology GH-pAbs. Two products will be in clinic in oncology in 2023, XON7, its lead pan-cancer targeting solid tumors and LIS22 in peripheral T-Cell lymploma.

Pipeline
Products in development

Latest
News

contact@xenothera.com
Publié par contact@xenothera.com
9 novembre 2022

[Newsletter] XENONEWS

November 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

More
contact@xenothera.com
Publié par contact@xenothera.com
18 juillet 2022

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

More
contact@xenothera.com
Publié par contact@xenothera.com
4 juillet 2022

[Newsletter] XENONEWS

June 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

More
XENOTHERA’s worldwide network
XENOTHERA is built on a worldwide network of scientific & medical collaboration.

Related
scientific papers

 

XENOTHERA is a start-up in biotechnology, developing innovative immunological treatments, specialized in oncology, and other therapeutic domains.

Investors already trusted us since creation by funding the company more than 46M€. Our products are expected to address unsolved major public health issues.

Our vision is to bring new approaches to the patients, as

INNOVATIVE LAB FOR RESPONSIVE CARE .

To contact us, use the form or see our full contact below:

XENOTHERA

21 rue La Nouë Bras de Fer – 44200 Nantes – France

To work with us: careers@xenothera.com

Press Contact: IZsoGOOD – Ingrid Zémor – xenothera@izsogood.co

 

  • Home
  • Expertise
  • Team
  • About
  • About pipeline
  • News
  • Partnerships
  • Publications
  • Contact form
  • Contact